Actinium Pharmaceuticals (ATNM) SEC Filings & 10K Form $1.40 +0.18 (+14.75%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends Recent Actinium Pharmaceuticals SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView11/27/20243:30 PMActinium Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/14/20243:57 PMActinium Pharmaceuticals (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 11/12/202412:33 PMActinium Pharmaceuticals (Subject)VANGUARD GROUP INC (Filed by)Form SC 13G/A11/08/20245:51 PMActinium Pharmaceuticals (Subject)Bigger Capital, LLC (Filed by)Form SC 13G/A11/06/20246:30 AMActinium Pharmaceuticals (Filer)Form ARS11/05/20244:00 PMActinium Pharmaceuticals (Filer)Form DEF 14A11/05/20244:05 PMActinium Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/05/20244:10 PMActinium Pharmaceuticals (Issuer)Almenoff June Sherie (Reporting)Form 3Initial statement of beneficial ownership of securities 11/05/20244:12 PMActinium Pharmaceuticals (Issuer)Almenoff June Sherie (Reporting)Form 4Statement of changes in beneficial ownership of securities 11/04/202410:47 AMActinium Pharmaceuticals (Subject)VANGUARD GROUP INC (Filed by)Form SC 13G11/04/202410:10 AMActinium Pharmaceuticals (Subject)VANGUARD GROUP INC (Filed by)Form SC 13G/A08/05/20246:30 AMActinium Pharmaceuticals (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 03/29/20243:58 PMActinium Pharmaceuticals (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 03/29/20244:00 PMActinium Pharmaceuticals (Filer)Form S-8Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans 02/09/20243:30 PMActinium Pharmaceuticals (Subject)Bigger Capital, LLC (Filed by)Form SC 13G/A02/05/202411:15 PMActinium Pharmaceuticals (Filer)Form EFFECT02/02/20244:03 PMActinium Pharmaceuticals (Filer)Form S-3/A01/29/20242:26 PMActinium Pharmaceuticals (Subject)BlackRock Inc. (Filed by)Form SC 13G(Data available from 1/1/2016 forward) Related Companies and Tools Related Companies ACTU SEC Filings CKPT SEC Filings PBYI SEC Filings CDTX SEC Filings IPHA SEC Filings ADAP SEC Filings BMEA SEC Filings FATE SEC Filings STRO SEC Filings TCRX SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NYSE:ATNM) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
